Evidence map›Paper›PMID 30417143›Full record

ArticleSynthetic and systems biotechnology2018

Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228.

Xiangyang Liu, Feng Xie, Leah B Doughty, Qi Wang, Lixin Zhang, Xueting Liu, Yi-Qiang Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic and systems biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Journal of natural products · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Xiangyang LiuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, PR China.
Feng XieCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, PR China.
Leah B DoughtyDepartment of Biological Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA.
Qi WangCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, PR China.
Lixin ZhangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, PR China.
Xueting LiuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, PR China.
Yi-Qiang ChengUNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.
University of North Texas · USChinese Academy of Sciences · CNEast China University of Science and Technology · CNUniversity of Wisconsin–Milwaukee · US

Funding

Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer AgentsR01CA152212 · NCI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI CHENG, ERIC YIQIANG · 2010 to 2014
$1.1M
NCI NIH HHS R01 CA152212
6 · The paper itself

Abstract

FK228 is an FDA-approved anticancer drug naturally produced by

Indexed as

Burkholderia thailandensis MSMB43Fermentation optimizationFK228Genome miningNatural productProductivity

Identifiers

PMID30417143
PMCPMC6222137
OpenAlexW2900411361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.